Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
Portfolio Pulse from
Roche has received FDA clearance and a CLIA waiver for its cobas® liat molecular tests, which diagnose sexually transmitted infections at the point of care. These tests will soon be available in the U.S. market.
January 22, 2025 | 6:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roche's cobas® liat molecular tests for STIs have received FDA clearance and a CLIA waiver, allowing for point-of-care diagnosis in the U.S. This regulatory approval could enhance Roche's market presence in the U.S. healthcare sector.
The FDA clearance and CLIA waiver for Roche's cobas® liat tests allow the company to enter the U.S. market with a new product offering. This regulatory approval is likely to positively impact Roche's stock as it expands its product portfolio in a significant market.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90